Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-12-19 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD
Foreign Filer Report
2022-12-19 English
IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT
Foreign Filer Report
2022-12-19 English
UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL
Foreign Filer Report
2022-12-19 English
FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF
Foreign Filer Report
2022-12-19 English
Enhertu recommended for EU approval in HER2-low BC
Regulatory Filings Classification · 1% confidence The document is a press release dated December 19, 2022, originating from AstraZeneca PLC, identified by the RNS Number '0763K' and the presence of the 'National Storage Mechanism' header. The content details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the approval of the drug Enhertu in the EU for a specific type of breast cancer. This is a corporate announcement regarding regulatory progress and clinical trial results, not a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT). Since it is a formal announcement of a significant corporate/regulatory event distributed via the RNS system, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), it falls best under the general Regulatory Filings (RNS) category, which serves as a broad category for official company news releases distributed through regulatory channels.
2022-12-19 English
Enhertu approved in EU for gastric cancer
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca dated December 19, 2022, announcing that their drug Enhertu has been approved in the European Union (EU) for a specific type of gastric cancer. It details the basis for the approval (clinical trial results like DESTINY-Gastric02 and DESTINY-Gastric01), provides quotes from executives and doctors, and mentions associated financial milestones. This content is characteristic of an official announcement regarding a significant corporate or product development, but it is not a formal regulatory filing like a 10-K, nor is it a transcript or a general earnings release. Since it is a specific announcement about a regulatory/product milestone that doesn't fit perfectly into the other specific categories (like DIV, CAP, or MANG), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements, or potentially an Earnings Release (ER) if it contained summary financials, but here the focus is purely on the approval and trial data. Given the nature of an RNS Number (0762K) being present, RNS is the most appropriate classification for a general regulatory announcement that isn't a core financial report.
2022-12-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.